Patent · US Active

Combinations for the treatment of cancer

US10869864B2 · kind B2 · utility

1Cited by

23References

15Claims

0Family size

Assignee

Ignyta, Inc. · US

Inventors

Gang Li · Beijing, CN
Ge Wei · San Diego, US
Zachary D. Hornby · San Diego, US
Jonathan Lim · San Diego, US

Key dates

Filing date	Dec 15, 2016
Grant date	Dec 22, 2020
Priority date	—
Expiry date	Dec 15, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Q2600/156
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Described herein are combinations comprising a therapeutically effective amount of a first agent and a therapeutically effective amount of a second agent, wherein the first agent is an inhibitor of ALK, ROS1, TrkA, TrkB, or TrkC activity, or a combination thereof, and methods of using such combinations in the treatment of patients having cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.